view페이지

Clinical trial of TEW-7197 starts its first step.

Jul 17, 2014EVENTSHit 2546

MedPacto, Inc. completed the fully executed site contract for one of three clinical sites for TEW-7197 in the USA on 18th July, 2014 (NCT02160106). TEW-7197 is the forefront asset of MedPacto's oncology pipeline and it is for cancer patients of solid tumors. The phase 1 trial is planned to complete in April of 2016.

About TEW-7197.
TEW-7197 is an inhibitor of ALK5 (TGF-beta receptor 1) which is a small molecule for oral formulation. It blocks TGF-beta signaling efficiently and it showed an excellent profile of safety and potency in non-clinical studies. It has a potential for the best-in-class oncology drug in its class.
Attachments
Next The first dosing of TEW-7197 in a cancer patient in the USA
Previous MedPacto gets an approval of IND for TEW-7197 from US FDA
List